Mechanistically, chimeric genes result from DNA rearrangements and include parts of
preexisting normal genes combined at the genomic junction site. Some rearranged genes …

Introduction Gene fusion testing of ALK, ROS1, RET, NTRK, and MET exon 14 skipping
mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless …

The majority of NTRK1, NTRK2, and NTRK3 rearrangements result in increased expression
of the kinase portion of the involved gene due to its fusion to an actively transcribed gene …

Gene fusions and MET exon skipping drive oncogenesis in 8–9% and 3% of non-small cell
lung cancers (NSCLC) respectively. Their detection are essential for the management of …

Simple Summary Updated international guidelines suggest NGS as the preferred procedure
for NSCLC patients' evaluation for predictive biomarkers, but NGS facilities are not available …

Tropomyosin receptor kinase (TRK) inhibitors have been approved for metastatic solid
tumors harboring NTRK fusions, but the detection of NTRK fusions is challenging …

Aberrant activation of tropomyosin receptor kinases (TRKs) is a well-defined oncogenic
driver for neurotrophic tropomyosin receptor kinase (NTRK)-fusion cancers, and acquired …

Introduction Gene rearrangements are frequent oncologic drivers in NSCLC, and many are
suitable for treatment with Food and Drug Administration–approved or experimental targeted …

Aims We aimed to evaluate the performances of the Idylla GeneFusion Assay (IGFA)
designed to detect, in a single, rapid and fully automated assay, ALK, ROS1, RET, NTRK1 …

Best practice in the management of non-squamous, non-small-cell lung cancer patients
involves somatic testing for a range of molecular markers. Actionable oncogenic drivers of …